T. Rowe Price Associates
EGRX

T. Rowe Price Associates’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

T. Rowe Price Associates’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-13,300
Closed -$50K – 3100
2024
Q3 		$50K Hold
13,300
– – ﹤0.01% 2929
2024
Q2 		$75K Sell
13,300
-2,448
-16% -$10.7K ﹤0.01% 2792
2024
Q1 		$83K Buy
+15,748
New +$86.4K ﹤0.01% 2811
2023
Q1 		– Sell
-15,893
Closed -$465K – 2962
2022
Q4 		$465K Buy
15,893
+1,018
+7% +$32.4K ﹤0.01% 2159
2022
Q3 		$393K Buy
14,875
+5,231
+54% +$192K ﹤0.01% 2250
2022
Q2 		$428K Sell
9,644
-3,444
-26% -$158K ﹤0.01% 2283
2022
Q1 		$648K Sell
13,088
-179
-1% -$8.59K ﹤0.01% 2224
2021
Q4 		$676K Sell
13,267
-208
-2% -$10.8K ﹤0.01% 2243
2021
Q3 		$752K Sell
13,475
-10
-0.1% -$492 ﹤0.01% 2190
2021
Q2 		$577K Sell
13,485
-1,554
-10% -$64.1K ﹤0.01% 2324
2021
Q1 		$628K Sell
15,039
-4,801
-24% -$223K ﹤0.01% 2256
2020
Q4 		$924K Sell
19,840
-6,103
-24% -$285K ﹤0.01% 1983
2020
Q3 		$1.1M Buy
25,943
+7,156
+38% +$313K ﹤0.01% 1753
2020
Q2 		$901K Sell
18,787
-1,449
-7% -$72.3K ﹤0.01% 1837
2020
Q1 		$931K Buy
20,236
+4,464
+28% +$224K ﹤0.01% 1732
2019
Q4 		$948K Buy
15,772
+500
+3% +$29.8K ﹤0.01% 1906
2019
Q3 		$864K Buy
15,272
+250
+2% +$14.1K ﹤0.01% 1881
2019
Q2 		$836K Buy
15,022
+20
+0.1% +$1.04K ﹤0.01% 1912
2019
Q1 		$757K Buy
15,002
+54
+0.4% +$2.4K ﹤0.01% 1964
2018
Q4 		$602K Buy
14,948
+1,818
+14% +$93.7K ﹤0.01% 2006
2018
Q3 		$910K Buy
13,130
+4,121
+46% +$312K ﹤0.01% 1907
2018
Q2 		$682K Buy
9,009
+37
+0.4% +$2.33K ﹤0.01% 2008
2018
Q1 		$473K Buy
8,972
+68
+0.8% +$3.95K ﹤0.01% 2111
2017
Q4 		$476K Sell
8,904
-23,234
-72% -$1.29M ﹤0.01% 2111
2017
Q3 		$1.92M Sell
32,138
-19,227
-37% -$1.16M ﹤0.01% 1589
2017
Q2 		$4.05M Buy
51,365
+45,196
+733% +$3.7M ﹤0.01% 1439
2017
Q1 		$512K Sell
6,169
-5,000
-45% -$372K ﹤0.01% 2061
2016
Q4 		$886K Buy
11,169
+1,764
+19% +$128K ﹤0.01% 1825
2016
Q3 		$658K Buy
+9,405
New +$521K ﹤0.01% 1906

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $984M AUM 72.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $508M AUM 24.82% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

T. Rowe Price Associates's EGRX Position: Q4 2024 in Review

T. Rowe Price Associates sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 13,300 shares — an estimated $50K sold.

T. Rowe Price Associates first reported a position in EGRX in Q3 2016 and held it in 29 quarters. The position peaked at $4.05M in Q2 2017. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • T. Rowe Price Associates reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 13,300 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $50K.
  • T. Rowe Price Associates first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 29 quarters.
  • T. Rowe Price Associates's Eagle Pharmaceuticals, Inc. position peaked at $4.05M in Q2 2017.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on T. Rowe Price Associates's 13F filing for Q4 2024, filed 14 Feb 2025.